Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Finch Therapeutics Group
200 Inner Belt Road, Suite 400
Somerville, MA 02143
Phone: 617-229-6499
http://finchtherapeutics.com/

Finch Therapeutics Group is developing novel microbial therapies to serve patients with serious unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses innovative machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience, building upon the science of fecal transplantation. Finch uses this human-first discovery approach to identify strains that drive clinical outcomes, developing therapies that deliver these microbial communities to patients. Through a strategic merger with Crestovo in 2017, Finch established a leading position in addressing the C. difficile epidemic with Crestovo's lead Full-Spectrum Microbiota product, CP101, which is currently being evaluated among patients suffering from recurrent C. difficile infections.

Key Contact
Name
Mark Smith
Title
CEO
Funding Events

Date
Amount
Type
Investors
03/05/18 $36,000,000 Series B Avenir Growth Capital
Morgan Noble
Shumway Capital
Willett Advisors
08/23/19 $53,000,000 Series C Avenir Growth Capital
Morgan Noble
OCV Partners
Shumway Capital
Susquehanna International Group
Symbiosis
Trans-Pacific Partners
Willett Advisors
09/17/20 $90,000,000 Series D Avenir Growth Capital
Baupost Group
Humboldt Fund
MSD Capital
MSD Partners
Octave Life Sciences
OCV Partners
OMX Ventures
Shumway Capital
SIG
Symbiosis
TPTF